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Abstract
Background: The prostate stroma is a key mediator of epithelial differentiation and development,
and potentially plays a role in the initiation and progression of prostate cancer. The tumor-
associated stroma is marked by increased expression of CD90/THY1. Isolation and
characterization of these stromal cells could provide valuable insight into the biology of the tumor
microenvironment.
Methods: Prostate CD90+ stromal fibromuscular cells from tumor specimens were isolated by
cell-sorting and analyzed by DNA microarray. Dataset analysis was used to compare gene
expression between histologically normal and tumor-associated stromal cells. For comparison,
stromal cells were also isolated and analyzed from the urinary bladder.
Results: The tumor-associated stromal cells were found to have decreased expression of genes
involved in smooth muscle differentiation, and those detected in prostate but not bladder. Other
differential expression between the stromal cell types included that of the CXC-chemokine genes.
Conclusion: CD90+ prostate tumor-associated stromal cells differed from their normal
counterpart in expression of multiple genes, some of which are potentially involved in organ
development.
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Background
Prostate stromal mesenchyme fibromuscular cells provide
a regulatory extracellular matrix and direct epithelial dif-
ferentiation and development through growth factors and
androgen stimulation [1]. The critical role stromal cells
play in prostate development has been demonstrated by
co-implantation in animals of stem cells and stromal cells
to achieve functional glandular development [2-7].
Although prostate cancer is epithelial in origin, there is a
growing body of evidence suggesting that the stromal
microenvironment plays a significant role in the cancer
process [8-12]. Prostate tumor-associated or 'reactive'
stroma is characterized by a decrease in smooth muscle
cell differentiation and an increase in myofibroblasts and
fibroblasts, with characteristics of a wound repair stroma
[13]. Defining the gene expression changes in the stroma
of prostate cancer has been the focus of several recent
studies and is an important step in defining the underly-
ing mechanisms of stromal-epithelial interaction in can-
cer. Previous studies have characterized gene expression
profiles of tumor-associated stromal cells isolated by
laser-capture microdissection (LCM) [14,15] and cultures
established from histologically confirmed cancer tissues
[16]. These studies have identified genes that are poten-
tially involved in processes such as proliferation and ang-
iogenesis. Current thought is that the tumor-associated
stroma always co-exists with cancer [17], and that it may
contribute to the gain of metastatic potential by tumor
cells and the progression towards androgen-independ-
ence [12].
In this study, we sought to identify genes specific to pros-
tate stromal cells that might function in organ specific
stromal induction of epithelial development, and to iso-
late viable stromal cell populations associated with cancer
by magnetic cell sorting (MACS) for gene expression anal-
ysis and comparison between these cells and their normal
counterpart [18-20]. CD90/THY1 is a cell surface mole-
cule expressed in a wide variety of cells including stem and
progenitor cells [21-27]. It is thought to be involved in cell
recognition, adhesion, and lymphocyte activation [26].
Elevated expression of CD90 has been found in the stro-
mal cells of primary prostate cancer [28]. Previously,
CD90hi cells isolated from primary stromal cell cultures of
prostate cancer were shown to differentially express sev-
eral genes associated with tumor-promotion [16]. Here,
we used differential expression of CD90 to isolate viable
CD90-expressing stromal cells directly from prostate can-
cer specimens for gene expression profiling and compari-
son to normal tissue stromal cells. We also used
differential expression of CD13 in the bladder stroma to
isolate viable CD13-expressing stromal cells from bladder
cancer specimens for further comparison. To date there
has not been an established marker comparable to CD90
in prostate stroma that differentiates bladder tumor-asso-
ciated stroma from normal. A population of CD13+ cells
in the so-called superficial lamina propria was regarded
here as the prostate-equivalent bladder stromal cells
because of its proximity to the urothelium [20]. These
profiles provide important cell-type specific gene expres-
sion data for future in vitro differentiation and develop-
ment studies to compare cancer-associated and normal
tissue stromal cells. We used cell sorting rather than LCM
because cell sorting results in a viable population that
could subsequently be grown in cell culture whereas LCM
cannot. Identification and isolation of a viable, suffi-
ciently pure, cancer-associated stromal cell population
from tumor specimens will provide an essential research
tool for the study of prostate carcinogenesis.
Methods
Tissue specimens
The methods of tissue collection, expression data genera-
tion and analysis used in this study have been published
previously [19,29,30]. The tissue samples consisted of
prostate tissue specimens obtained from 13 patients
undergoing radical prostatectomy under approval by the
University of Washington Institutional Review Board. The
same approach was used for both cancer-free and cancer-
enriched (where at least 85% of the cells in the corre-
sponding frozen section were of cancer) samples. Upon
receipt of a radical specimen, 3-mm thick transverse sec-
tions were made of the prostate after inking the exterior
surface. Cancer-free samples, weighing between 2 and 10
g, were harvested primarily from the anterior aspect of the
prostate (transition zone) as described [19,20,31]. Corre-
sponding frozen sections were histologically assessed to
confirm the specimens were free of cancer. Cancer-
enriched samples, weighing at least 0.1 g, were dissected
from the opposing aspect of the non-fixed section adja-
cent to the block of tissue that had been sectioned. To
minimize possible RNA degradation, organs resected in
the operating room were immediately submerged in ice-
cold saline solution. The pathology characteristics of the
tumors from which stromal cells were obtained were as
follows - 08-021: Gleason 5+4, T3a, 4.5 cc tumor volume;
08-028: Gleason 3+4, T2c, 2.5 cc; 08-032: Gleason 4+4,
T3b, 27 cc. Whole tissue transcriptomes were generated
from the following tumor samples - 05A: Gleason 3+4,
T3a, 6 cc; 05B: Gleason 3+4, T2c, 3.4 cc; 05C: Gleason
4+5, T3a, 3 cc; 05D: Gleason 4+5, T3aN1, >5 cc; 05E:
Gleason 3+4, T2a, 2.5 cc; and their matched non-cancer
samples.
To obtain bladder stromal cells for analysis, tissue speci-
mens were obtained from cystoprostatectomy specimens.
Transverse sections of intact urethra and both ureters were
taken to assess the surgical margins. After palpating the
bladder externally to locate any masses and inking grossly
concerning lateral surgical margin(s), the bladder was
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opened, avoiding transecting the tumor. Regions of blad-
der mucosae and wall that appeared grossly normal both
visually and by palpation were identified as "normal" uri-
nary bladder. An approximately 2 × 2 cm portion of blad-
der wall with minimal perivesicle fat was excised and cut
into several pieces. Two pieces were histologically charac-
terized to verify that the tissue collected was free of either
invasive or in situ carcinoma. The others were used for cell
sorting. The pathology characteristics of the tumor from
which CB stromal cells were obtained was as follows:
specimen 07A contained was a high-grade urothelial car-
cinoma, stage pT2N0.
For cell sorting, the collected specimens were processed
within hours. The tissue was rinsed with Hanks balanced
salt solution (HBSS) and minced for enzymatic digestion
overnight at room temperature with 0.2% collagenase
type I (Invitrogen, Carlsbad, CA) in RPMI-1640 media
supplemented with 5% FBS and 10-8 M dihydrotestoster-
one or serum-free media on a magnetic stirrer. The result-
ant cell suspension was filtered with 70-μm Falcon cell
strainer, diluted with an equal volume of HBSS, and aspi-
rated with 18-gauge needle. The single cell preparation
was partitioned into stromal and epithelial fractions on a
discontinuous Percoll density gradient (Amersham Phar-
macia, Piscataway, NJ) as described previously [32,33].
Western blot analysis of digestion media
HBSS-diluted tissue digestion media was centrifuged and
the supernatant was collected. Protein concentrations
were measured using Bradford Assay (BioRad, Hercules,
CA). Sample buffer and 0.1 M DTT were added to amount
of media containing 60 μg protein. The samples were
heated to 70° for 10 min, electrophoresed on 4-20% gra-
dient SDS-polyacrylamide gel (BioRad), and electrotrans-
ferred to PVDF membrane (Hybond-P, Amersham). The
membrane was immersed in 5% nonfat dry milk in PBS-
Tween for 30 min, and probed with tissue inhibitor of
metalloproteinase 1 (TIMP1) antibody (1:500; MAB3300,
Millipore, Temecula, CA) or CD90 antibody (1:500;
5E10, BD-PharMingen, San Diego, CA) for 60 min, fol-
lowed by horseradish peroxidase conjugated anti-mouse
IgG. After washing, the membrane was incubated with
Luminol (Santa Cruz Biotechnology, Santa Cruz, CA) and
immunoreactive bands were visualized using Biomax MR
light film (Kodak, Rochester, NY). Prostate specific anti-
gen (PSA) antibody (1:1000; A67-B/E3, Santa Cruz) was
used for loading control.
MACS cell isolation
Cell types were sorted using monoclonal antibodies spe-
cific for tumor-associated prostate stromal cells (CD90),
tumor-associated bladder stromal cells (CD13) and nor-
mal bladder stromal cells (CD13) with MACS in the same
manner as was previously used to generate the normal
prostate stromal cell (CD49a) transcriptome [19]. The
gradient-purified stromal cell fraction was resuspended in
100 μl 0.1% bovine serum albumin (BSA)-HBSS, and
CD90-Phycoerythrin (PE) mouse monoclonal antibody
(1:20, 5E10, BD-PharMingen) or CD13-PE (1:20, WM15,
BD-PharMingen) added for 15 min at room temperature
in the dark. The reaction was stopped by 1 ml 0.1% BSA-
HBSS and centrifugation. The labeled cells were resus-
pended and 15 μl paramagnetic microbead conjugated
anti-PE antibody (Miltenyi Biotec, Auburn, CA) was
added for 15 min. After incubation the positive and nega-
tive cells were separated by AutoMACS cell sorter
(Miltenyi Biotec) using double positive sort program.
FACS analysis of sorted cells
Aliquots of positive and negative cell fractions were ana-
lyzed by fluorescence activated cell sorting (FACS) (Bec-
ton Dickinson, Mountain View, CA) to monitor the sort
efficiency; only >85% CD90+ and CD13+fractions were
used for microarray experiments. The purity level was cho-
sen based on our own observations (unpublished data)
and studies by Szaniszlo et al., that showed that the tran-
scriptome of a 75% pure sorted cell population is largely
identical to that of a 100% pure population [34]. The
sorted stromal cells were pelleted by centrifugation and
lysed immediately in RLT (Qiagen, Valencia, CA). Total
RNA was extracted for gene expression analysis using RNe-
asy (Qiagen).
Gene expression profiling on Affymetrix DNA microarrays
Quality and concentration of RNA were determined using
Agilent 2100 Bioanalyzer and RNA Nano or Pico Labchip
(Agilent Technologies, Santa Clara, CA). Only RNA sam-
ples that were of sufficient concentration and showed no
degradation as evidenced by distinct ribosomal bands at
18S and 28S were used for microarray experiments using
the Human Genome U133 Plus 2.0 GeneChips (Affyme-
trix, Santa Clara, CA). The U133 Plus 2.0 array contained
probesets representing 54,675 genes, splice variants, and
ESTs. The GeneChips were prepared, hybridized, and
scanned according to the protocols provided by Affyme-
trix (P/N 702232 Rev. 2). Briefly, 200 ng of RNA was
reverse transcribed with poly (dT) primer/T7 promoter,
and the cDNA was made double-stranded. In vitro tran-
scription was performed to produce unlabeled cRNA.
Next, first-strand cDNA was produced with random prim-
ers, and the cDNA was made double-stranded. In vitro
transcription was performed with biotinylated ribonucle-
otides, and the biotin-labeled cRNA was hybridized to the
GeneChips. The chips were washed and stained with
streptavidin-PE using Affymetrix FS-450 fluidics station.
Data was collected with Affymetrix GeneChip Scanner
3000. A total of 15 array datasets were obtained from the
following sample types obtained from 10 patients: two
CD90+ prostate tumor-associated stromal, two CD13+
BMC Cancer 2009, 9:317 http://www.biomedcentral.com/1471-2407/9/317
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normal bladder stromal, one CD13+ bladder tumor-asso-
ciated stromal, and five whole tissue prostate cancer and
five normal tissue from matched pairs. Additionally, 8
array datasets were obtained from the following sample
types obtained from 7 patients: five CD49a+ normal pros-
tate stromal (published previously [19]), and three CD26+
prostate cancer (with one sample analyzed twice, Pascal et
al., submitted). All datasets have been deposited in GEO
with the following accession number: GSE17906.
Microarray data analysis
Differential gene expression was determined by HTself, a
self-self based statistical method for individual microar-
rays [35]. All possible combinations of pair-wise compar-
isons among experiments were taken to create sets of
ratios. The test used virtual self-self experiments to derive
intensity-dependent cutoffs. Accordingly, a probeset was
considered significantly differentially expressed if all its
log-ratio combinations were outside the 99.9% credibility
cutoff. The computational analysis results were verified by
dataset query of known differentially expressed genes.
Pathway analysis of selected genes was done with KEGG.
Functional and ontology enrichment analysis was per-
formed using the DAVID web-based tool [36].
Gene expression validation
Reverse transcriptase polymerase chain reaction (RT-PCR)
and quantitative real-time PCR (qPCR) were used to vali-
date expression obtained by DNA arrays. For each cell/tis-
sue sample, 1 μg RNA was reverse transcribed with
Superscript II RT (Invitrogen) at 50° for 50 min followed
by 10 min at 70°. Gene-specific primers for PCR (Addi-
tional file 1) were designed to produce amplicons of 100-
650 bp in size. PCR was carried out at 95°/30 s, 55°/30 s,
72°/1 min for 35 cycles. PCR products were resolved on
2% agarose gels. Smooth muscle actin (ACTA2), ribos-
omal protein RPL0 and GAPDH served as internal refer-
ences for the various PCR experiments. Results were
derived from specimens different from those used for
transcriptome analysis.
Results
CP stromal cell transcriptomes
The transcriptomes were determined for both CD90+
prostate tumor-associated stromal cells and for CD13+
tumor-associated and normal bladder stromal cells, the
transcriptome for normal prostate stromal cells was deter-
mined previously [19]. For convenience, prostate tumor
tissue was designated here as CP and non-cancer as NP;
bladder tumor tissue was designated here as CB and non-
cancer as NB. The transcriptome datasets of cells and tis-
sue were deposited in our public database UESC [30]. For
MACS, a minimum of 0.5 g tissue specimen was required.
CD90+ CP stromal cells were successfully sorted from 08-
028 and 08-03; CD13+ CB from 07A; and CD13+ NB from
06A and 06B for Affymetrix GeneChip analysis. Sufficient
RNA was not obtained from the CD90 sort of 08-021.
CD90 was used based on prior finding that tumor-associ-
ated stromal cells were uniformly stained by the CD90
antibody within tumor foci [29]. In the bladder, CD
immunohistochemistry showed that CD13 could define a
population beneath the urothelium whereas the remain-
der was CD13-negative [20]. Prostate stromal cells are
CD13-. CD13-PE was used to sort CD13+ NB and CB blad-
der stromal cells for arrays. Western blot analysis of the
collagenase digestion media for CD90 and TIMP1 was
done to assess specimen purity. A 'pure' CP sample should
have minimal reactivity to TIMP1, which is secreted by
luminal cells and not by cancer cells [37]. Therefore, CP
samples that showed minimal TIMP1 reactivity were rela-
tively pure, i.e., with little 'contamination' of non-cancer
elements as shown for 08-028CP and 08-032CP in Figure
1A. The increase in CD90 also confirmed that these CP
specimens were from cancer. PSA was used as a sample
loading control.
Gene expression in CP vs. NP
In order to identify genes unique to tumor-associated
prostate stromal cells, differential gene expression was
analyzed for CD90-expressing stromal cells from the two
sorted cases and compared to previously determined
CD49a+ NP stromal cells, CD26+ CP cells, and other pros-
tate cell types determined previously in our lab
[19,20,30]. The data were reported as robust multi-array
average (RMA) [38] normalized Affymetrix signal intensi-
ties implemented in the in-house analysis pipeline
SBEAMS [39], or as a composite value: X = log2(Cancer
normalized intensity/Normal normalized intensity).
These data were made available for download from the
UESC database [18]. Dataset interrogation in UESC has
been described previously [18,30]. Figure 1B and 1C
showed that the CP stromal transcriptomes contained
minimal signals for epithelial genes such as ACPP (pros-
tatic acid phosphatase), AZGP1 (zinc α2-glycoprotein),
KLK2/hK2, KLK3/PSA, MSMB/PSP94, and epithelial cell
keratins (the cancer cell transcriptome [18], contained
luminal KRT8, KRT18, KRT19 expression and not that of
KRT5, KRT14, KRT17 for basal or intermediate cells [40]).
Therefore, CD90 sorting was efficient enough to exclude
cancer cells, the other major cell type of tumor tissue.
Some of the most down-regulated and up-regulated genes
in CD90+ CP stromal cells compared to CD49a+ NP stro-
mal cells and verified by whole tissue and CD26+ compar-
ison are shown in Figure 2. Although the whole tissue
transcriptome comparison of CP vs. NP showed decreased
overall differential expression in these same genes, they
were in agreement with the differential expression
between sorted CP vs. NP. This decrease could in part be
BMC Cancer 2009, 9:317 http://www.biomedcentral.com/1471-2407/9/317
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due to co-expression of these same genes by other cell
types within the tissue, or to a 'tissue-masking' effect [20].
Furthermore, the expression levels of many of these
tumor-associated stroma genes were below background
(50 RMA) in both CD26+ cancer and CD26+ luminal epi-
thelial cells.
Prostatic stromal cells are predominantly smooth muscle
cells (SMC), characterized by desmin/DES, caldesmon/
CALD1, α-smooth muscle actin/ACTA2 expression with
few myofibroblasts (ACTA2, vimentin/VIM expression)
and fibroblasts (VIM expression). In cancer, smooth mus-
cle expression is decreased [41]. There is also reported loss
of androgen receptor (AR) [42] and calponin (CNN1) [9]
expression. Table 1 compares expression level of these
genes and others as represented by gene array signal inten-
sities and overall fold-change between NP and CP stromal
cells and in agreement with whole tissue NP and CP tran-
scriptome comparison. At least a 4-fold decrease for
ACTA2, DES, CNN1, PENK, CNTN1, and 2-fold for
CALD1 was found in CP stromal cells. Decrease in expres-
sion of these genes was also found in whole tissue com-
parison, to a lesser degree. No significant difference was
seen for AR and VIM.
Identification of potential organ-specific stromal genes in 
cancer
Because of their central role in organ development, stro-
mal cells might be expected to show organ-specific gene
expression. Thus, by comparing the gene expression
between prostate and, for example, bladder stromal cells,
prostate-specific genes might be identified. A previous
report described such a comparison using cultured pros-
tate and bladder stromal cells, and cDNA microarray anal-
Isolation of CD90+ stromal cells from cancer tissueFigure 1
Isolation of CD90+ stromal cells from cancer tissue. A: Tissue digestion media were probed for TIMP1 and CD90 pro-
teins by Western blot analysis. Sample 00-044NP served as non-cancer control because 08-028NP and 08-032NP were not 
available. PSA was used as a sample loading control. B: The individual sorted CP stromal transcriptome datasets (second and 
third columns) contain minimal signals for the epithelial genes that are present in the cancer epithelial cell (CP cancer) tran-
scriptome (first column) in virtual Northern blot format. Affymetrix signal values are represented on a gray scale. C: The 
expression levels of epithelial genes are below background (≤ 50 RMA) in sorted CP stromal cells.
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ysis [20]. In the current report, sorted prostate and bladder
stromal cells were compared. Comparative dataset analy-
sis between CD13+ bladder stromal and CD49a+ prostate
stromal identified 91 bladder and 288 prostate differen-
tially expressed genes (Figure 3). Among the genes identi-
fied, prostate expression of SPOCK3 (sparc/osteonectin
proteoglycan/testican), MSMB, CXCL13 (chemokine lig-
and), PAGE4 (P antigen family member), and bladder
expression of TRPA1 (transient receptor potential cation
channel), HSD17B2 (hydroxysteroid 17-β dehydroge-
nase), IL24, SALL1 (Drosophila sal-like) were validated by
qPCR (Figure 3). The prostate stromal dataset was further
Sorted cell and whole tissue transcriptome dataset comparisonFigure 2
Sorted cell and whole tissue transcriptome dataset comparison. The most down-regulated (negative) and most up-
regulated (positive) genes in sorted tumor-associated stromal cells are also similarly expressed, for the majority, in whole tis-
sue comparison of CP to NP.
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Table 1: Smooth muscle differentiation in CP stromal cells.
CD49a+ NP CD90+ CP Fold change Whole tissue NP Whole tissue CP Fold change
ACTA2 5399 1117 -4.83 5369 2882 -1.86
AR 211 182 -1.16 341 392 1.15
DES 144 27 -5.36 1573 482 -3.27
CALD1 1794 936 -1.92 1617 1103 -1.47
VIM 6519 6153 -1.06 1983 1700 -1.17
CNN1 2437 299 -8.16 5856 1928 -3.04
PENK 3896 998 -3.90 239 86 -2.79
CNTN1 791 197 -4.02 157 95 -1.66
Affymetrix signal levels are tabulated for the genes selected, and the fold decrease in expression in CP stromal cells compared to NP is indicated for 
sorted cells and whole tissue.
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Organ-specific stromal genesFigure 3
Organ-specific stromal genes. A: Up-regulated genes in the bladder (left) and the prostate (right) are identified by brown 
colored data points. The horizontal axis represent the fraction of spot replicates above (p.up) or below (p.down) the differen-
tially expressed cutoff. The vertical axis represents the mean log-ratios. B: Shown are the qPCR results for prostate SPOCK3, 
MSMB, CXCL13, PAGE4, and bladder TRPA1, HSD17B2, IL24, SALL1. RPLP0 was used as reaction control. Light blue indicates 
prostate genes and red bladder genes.
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filtered by the previously determined prostate transcrip-
tome datasets of CD104+ basal, CD26+ luminal, and
CD31+ endothelial. If a gene was present in 3 or more rep-
licates, it was deemed as "present", and was removed from
the CD49a stromal dataset. This resulted in a list of 50
stromal-specific genes that could be slotted into 39 func-
tional categories using the software tools. Database query
showed that expression of these 50 genes was enriched in
sorted stromal cells as well as those obtained by laser-cap-
ture microdissection. The prostate stromal genes included
CNTN1 (contactin), SPOCK3 and MAOB (monoamine
oxidase), which all have been reported in the literature to
have a function in development.
Down-regulation of potential organ-specific stromal genes 
in cancer
Importance of the organ-specific stromal genes was sug-
gested by their abnormal expression in cancer. Previously,
we showed that expression of prostate-specific PENK was
down-regulated in cancer [20]. Figure 4A shows the tran-
scriptome data for the expression of identified prostate or
bladder stromal genes in cancer vs. normal. Down-regula-
tion was seen for CNTN1, CXCL13, MAOB, PAGE4,
PENK, SPOCK3 in CP compared to NP as well as for
HSD17B2, SALL1, TRPA1 for tumor-associated bladder
stromal cells compared to normal bladder. The down-reg-
ulation of these putatively prostate stromal-specific genes
was also evident in whole tissue CP vs. NP. With the excep-
tion of IL24 which is up-regulated 14-fold in CD26+ CP vs.
NP (see also Figure 5A), the expression level of these genes
is either below background or very low in prostate epithe-
lial cells (data not shown). RT-PCR analysis using
matched CP and NP cDNA specimens showed that, like
PENK, CNTN1 was detected in all NP samples, but its
level was either decreased or undetectable in CP (and
metastasis) samples (Figure 4B, bottom panel), while not
as notably down-regulated for MAOB and SPOCK3.
Smooth muscle actin (ACTA2) was used as control for
stromal cell representation in these samples. Also notable
was the increased CP expression of the bladder genes IL24
and SALL1 (IL24 was not down-regulated in CB). STC2
(stanniocalcin) is an example of a non-organ specific stro-
mal gene that appeared to be down-regulated in CB (07-
008); STC2 expression is higher in NB than NP [20].
Expression of CXC-chemokines in tumor-associated 
stroma
Chemokines of the CXC family are involved in chemoat-
traction and activation of specific leukocytes in various
immuno-inflammatory responses. They have also been
shown to play key roles in neoplastic transformation and
the passage of tumor cells through the endothelial vessel
wall and extracellular matrix in several tumor types,
including the prostate [43-47]. The expression of CXC
chemokines was compared in sorted CP vs. NP stromal
cells (Figure 5). Whole tissue comparison showed discrep-
ancies for CXCL1, CXCL3, CXCL5 and CXCL6 (Figure
5A), these differences could in part be due to their high
levels of expression in other prostate cell types (Figure
5B). The expression difference was assessed by RT-PCR of
sorted prostate stromal cells (Figure 5C). The fold changes
(in brackets) for CP/NP in array signal intensities for
CXCL1 (4), CXCL2 (0.9), CXCL3 (4), CXCL4/PF4 (2.5),
CXCL5 (85.6), CXCL6 (13), CXCL7/IL7 (0.4) and CXCL8
(1) were in good agreement with the RT-PCR results.
Discussion
In prostate cancer, both the epithelial and stromal com-
partments can be distinguished by CD immunostaining
from their normal/benign counterpart cell types [28]. CD
immunostaining can also distinguish stromal cells of the
prostate and the bladder [20]. Our data show that the stro-
mal cell type in cancer differs from that in normal/benign
in the expression of a significant number of genes, both
down-regulated and up-regulated. A recently reported
genome-wide analysis showed no somatic DNA changes
in breast and ovarian tumor-associated stromal cells [48]
so that DNA mutation could not likely contribute to the
expression alteration. With expression alteration, the
influence of CP stromal cells on epithelial differentiation
and function is consequently different from that of NP
stromal cells. The down-regulation of markers associated
with SMC differentiation and of organ-specific genes sug-
gests a loss of normal stromal signaling. We recently
developed a co-culture system in which NP stromal cells
were shown to induce differentiation of an embryonal
carcinoma stem-cell line into a cell type with stromal cell
gene expression, including the up-regulation of CNTN1,
as well as that of epithelial markers [49]. This system
could allow us to further explore the role of genes identi-
fied here in cell-cell interaction. Bladder stromal genes
could be similarly tested. The involvement of stromal cells
in cancer is a feature of the tissue organization theory of
carcinogenesis [50], which equates cancer to inborn errors
of development. Cancer is characterized by disruption of
reciprocal intercellular signaling that maintains tissue
organization in repair and turnover. For example, irradia-
tion of breast stroma caused tumor formation from
implanted non-irradiated mammary epithelial cells while
non-irradiated stroma did not [51]. Of the down-regu-
lated genes, PENK is a hormone known to function in
development [52]. CNTN1 is known to mediate cell sur-
face interactions in the development of the nervous sys-
tem by signaling between axons and myelinating glial
cells [53] and has been shown to promote cellular adhe-
sion and invasion of lung cancer cells [54]. Also, CNTN1
has been shown to promote differentiation in CD90+
bone marrow stromal cells [55]. Both PENK and CNTN1
have been detected in the prostate in other studies
[52,56], and cancer down-regulation of PENK was evident
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in published datasets [52]. SPOCK3 encodes a secreted
protein involved in diverse steps of neurogenesis [57] and
has been shown to inhibit tumor invasion [57]. MAOB
catalyzes oxidative deamination of biogenic and xenobi-
otic amines with important roles in the metabolism of
neuroactive and vasoactive amines in the central nervous
system and peripheral tissues [58]. CNTN1 was detected
here all NP samples analyzed, down-regulated in CP, and
not detected in metastasis. A similar pattern is shown by
MAOB and SPOCK3 to a lesser degree. MAOB was found
to be expressed in lymph node metastases. The down-reg-
ulation of organ-specific genes appears to be a feature also
of bladder cancer-associated stromal cells. Future analyses
such as transcriptome determination of the various cell
types in the bladder will be required to more fully under-
stand the role of stromal-epithelial interaction in bladder
carcinogenesis. TRPA1 functions in signal transduction
and growth control, HSD17B2 may have a role in bone
development, and SALL1 a role in kidney development.
Interestingly, the bladder stromal genes SALL1 and IL24
appear to be expressed in CP stromal cells.
In addition, these cancer-associated stromal cells could
also be the source of potential cancer biomarkers conse-
quential to their production of secreted/extracellular pro-
tein products. For each cancer epithelial cell, there are
about 5-10 associated CP stromal cells (True et al., submit-
ted); as a result, a higher concentration of stromal-derived
markers such as those identified here would be expected.
The cell surface-anchored CD90 was detected in tissue
digestion media [37] as well as in media of cultured stro-
mal cells [59]. The increase in CD90 protein in cancer tis-
sue was measured by quantitative proteomics [37] and
was detectable by Western blot analysis. Therefore,
secreted proteins like SFRP4 with a 12-fold increase in
expression in tumor-associated stroma could potentially
serve as markers for the presence of cancer. With appropri-
ate antibodies, ELISA-type of assays could be developed
for these marker proteins. Alternatively, multiplex-type of
assays could be designed to detect these genes. The abnor-
mal expression of Wnt pathway member SFRP4 and WT1
in stromal cells and that of other members in the epithe-
lial cancer cells (Pascal et al., submitted) suggest a signifi-
cant role of Wnt signaling in prostate carcinogenesis.
Two published datasets of tumor-associated vs. normal
tissue stromal cells were available for comparison to ours.
Genes scored as up-regulated (no down-regulated ones
were found) by Richardson et al. [14] did not match those
by Zhao et al. [16]. Expression of only a subset of these
genes was scored as up-regulated in our datasets. The
method of cell isolation could be a factor. Richardson et
al. used laser-capture microdissection, but without immu-
nostaining (e.g., with CD90) it is difficult to avoid captur-
ing any NP stromal since the cancer-associated stroma
does not extend beyond 10 cells from the tumor glands
(True et al., submitted). Zhao et al. used cultured CP and
NP stromal cells. Cell culturing is known to alter gene
expression (e.g., expression of epithelial CD markers
[31]). The datasets of Joesting et al. [60] were also gener-
ated from cultured cells but did not match well with those
of Zhao et al. In addition, incorrect array probesets and
non-agreement between array signals and protein expres-
sion determined by immunostaining could compromise
data quality [18]. Our finding that genes involved in SMC
differentiation and organ specificity were down-regulated
in CP stromal cells is in line with the hypothesis that stro-
mal cell differentiation in tumor is abnormal. The up-reg-
ulation of CD90 is notable because CD90 is a stem cell
marker, and CD90+ fibroblasts are considered to be a
primitive cell type. Attenuated smooth muscle differentia-
tion and down-regulation of developmental genes such as
Differential expression of organ-specific stromal genes in cancerFigu  4
Differential expression of organ-specific stromal 
genes in cancer. A: Genes found to be differentially 
expressed in sorted tumor-associated stromal cells of blad-
der and prostate and prostate tissue. B: CP and NP are 
matched cancer and non-cancer prostate specimens; bone, 
liver and LN (lymph node) are prostate cancer metastasis 
specimens. CNTN1 is detectable in all NP, but it is down-
regulated in CP; not detected in metastasis. A similar pattern 
is shown by MAOB and SPOCK3, but the differential expres-
sion is not as pronounced. MAOB is expressed in LN. cDNA 
quantity of each sample was monitored by ACTA2 (shown 
for CP1/NP1).
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CNTN1, SPOCK3 and MAOB are an indication of such a
possibility. Furthermore, the possibility exists that these
tumor-associated stromal cells are similar to the normal
stromal cells adjacent to the basal epithelium. Future
comparison of the tumor-associated stromal cells to
CD90+ normal stromal cells may provide even greater
insight into the role of stromal-epithelial interaction and
how it might be disrupted in prostate carcinogenesis.
The cancer stroma contains not only fibromuscular cells
but also CD45+ white blood cells, CD31+ endothelial cells
of blood vessels, and nerve elements. These cell types
could conceivably have a function in the cancer process as
well [61,62]. Similar experimental analyses can be used to
characterize and compare these cell types isolated from
tumor and normal tissue.
Conclusion
The results reported here provide evidence that gene
expression of tumor-associated stromal cells differs from
that of normal tissue stromal cells. Some of the genes
affected have role in smooth muscle differentiation and
reported function in organ development. These changes
could in effect alter the functional property of stromal
cells, in particular, in intercellular signaling in the tumor.
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Expression of CXC-chemokines in stromal cellsFigure 5
Expression of CXC-chemokines in stromal cells. A: Differential expression of CXC-chemokines in sorted CD90+ CP vs. 
CD49a+ NP stromal cells and comparison to whole tissue CP vs. NP and CD26+ CP vs. NP. B: Virtual Northern display of 
expression levels of CXCL1, CXCL3, CXCL5 and CXCL6 in other prostate cell types (darker shading of the boxes indicates 
higher mRNA levels). C: RT-PCR verification of differentially expressed CXC-chemokines in sorted CD90+ CP and CD49a+ 
NP stromal cells.
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